Sage Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Sage Therapeutics's estimated annual revenue is currently $97.7M per year.(i)
  • Sage Therapeutics received $575.0M in venture funding in February 2018.
  • Sage Therapeutics's estimated revenue per employee is $127,148
  • Sage Therapeutics's total funding is $1.1B.

Employee Data

  • Sage Therapeutics has 768 Employees.(i)
  • Sage Therapeutics grew their employee count by 4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Sage Therapeutics News

2022-04-20 - Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health,...

2022-04-19 - Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of “Hold” from Brokerages. Posted by admin on Apr 18th, 2022.

2022-04-06 - Sage Therapeutics Announces Presentation of Promising ...

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to...

2021-03-17 - Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to naturalistically fol ...

2020-12-31 - Sage Therapeutics, Inc. announced that it has received $649.986998 million in funding from Biogen MA Inc.

On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Sage Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$20.0MBARCH Venture PartnersArticle
2015-04-15$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-22$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-11-15$345.0MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-09$575.0MUndisclosedJ.P. Morgan Securities LLCArticle